The Year in Epidemiology, Health Services Research, and Outcomes Research

Journal of the American College of Cardiology

Volumn 48, Issue 9, 2006, Pages 1886-1895

  Krumholz, Harlan M ^a   Masoudi, Frederick A ^b  

^a Robert Wood Johnson Clinical Scholars Program   (United States)

^b DENVER HEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; APROTININ; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEGA 3 FATTY ACID; PACLITAXEL; PRAVASTATIN; RAPAMYCIN; RIMONABANT; ROSUVASTATIN; SIMVASTATIN; SPIRONOLACTONE; TRANILAST; WARFARIN;

ANGINA PECTORIS; ARTERY CATHETERIZATION; ARTIFICIAL HEART PACEMAKER; BLEEDING; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEFIBRILLATOR; DRUG ELUTING STENT; DRUG SAFETY; DYSLIPIDEMIA; EPIDEMIOLOGICAL DATA; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH SERVICES RESEARCH; HEART ARREST; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE TACHYCARDIA; HUMAN; IN-STENT RESTENOSIS; INFECTION COMPLICATION; KIDNEY DISEASE; KIDNEY FAILURE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL ERROR; META ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRESCRIPTION; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RACE DIFFERENCE; REVIEW; RHABDOMYOLYSIS; SEX DIFFERENCE; SYSTEMATIC REVIEW;

CARDIOVASCULAR DISEASES; EPIDEMIOLOGIC RESEARCH DESIGN; HEALTH SERVICES RESEARCH; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 33751065397     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.09.006     Document Type: Review

References (98)

1. Mehta R.H., Alexander J.H., Van de Werf F., et al. Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes. JAMA 293 (2005) 1746-1750
2. Alexander K.P., Chen A.Y., Roe M.T., et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294 (2005) 3108-3116
3. Rothberg M.B., Celestin C., Fiore L.D., Lawler E., and Cook J.R. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 143 (2005) 241-250
4. Heneghan C., Alonso-Coello P., Garcia-Alamino J.M., et al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 367 (2006) 404-411
5. Alsheikh-Ali A.A., Ambrose M.S., Kuvin J.T., and Karas R.H. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 111 (2005) 3051-3057
6. Dale K.M., Coleman C.I., Henyan N.N., Kluger J., and White C.M. Statins and cancer risk: a meta-analysis. JAMA 295 (2006) 74-80
7. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
8. Poynter J.N., Gruber S.B., Higgins P.D., et al. Statins and the risk of colorectal cancer. N Engl J Med 352 (2005) 2184-2192
9. McDonald M.A., Simpson S.H., Ezekowitz J.A., Gyenes G., and Tsuyuki R.T. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ 331 (2005) 873-876
10. Demers C., McMurray J.J., Swedberg K., et al. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA 294 (2005) 1794-1798
11. Masoudi F.A., Gross C.P., Wang Y., et al. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. Circulation 112 (2005) 39-47
12. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
13. Mangano D.T., Tudor I.C., and Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354 (2006) 353-365
14. Katritsis D.G., and Ioannidis J.P. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation 111 (2005) 2906-2912
15. Devereaux P.J., Beattie W.S., Choi P.T., et al. How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery?. Systematic review and meta-analysis of randomised controlled trials. BMJ 331 (2005) 313-321
16. Mehta S.R., Cannon C.P., Fox K.A., et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 293 (2005) 2908-2917
17. Keeley E.C., Boura J.A., and Grines C.L. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 367 (2006) 579-588
18. Lindholm L.H., Carlberg B., and Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension?. A meta-analysis. Lancet 366 (2005) 1545-1553
19. Hannan E.L., Wu C., Walford G., et al. Volume-outcome relationships for percutaneous coronary interventions in the stent era. Circulation 112 (2005) 1171-1179
20. Schelbert E.B., Vaughan-Sarrazin M.S., Welke K.F., and Rosenthal G.E. Hospital volume and selection of valve type in older patients undergoing aortic valve replacement surgery in the United States. Circulation 111 (2005) 2178-2182
21. Al-Khatib S.M., Lucas F.L., Jollis J.G., Malenka D.J., and Wennberg D.E. The relation between patients' outcomes and the volume of cardioverter-defibrillator implantation procedures performed by physicians treating Medicare beneficiaries. J Am Coll Cardiol 46 (2005) 1536-1540
22. Granger B.B., Swedberg K., Ekman I., et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 366 (2005) 2005-2011
23. Fox K.A., Poole-Wilson P., Clayton T.C., et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet 366 (2005) 914-920
24. Binanay C., Califf R.M., Hasselblad V., et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 294 (2005) 1625-1633
25. GESICA Investigators. Randomised trial of telephone intervention in chronic heart failure: DIAL trial. BMJ 331 (2005) 425-427
26. Barnfather K.D., Cope G.F., and Chapple I.L. Effect of incorporating a 10 minute point of care test for salivary nicotine metabolites into a general practice based smoking cessation programme: randomised controlled trial. BMJ 331 (2005) 999-1001
27. Fumagalli S., Boncinelli L., Lo Nostro A., et al. Reduced cardiocirculatory complications with unrestrictive visiting policy in an intensive care unit: results from a pilot, randomized trial. Circulation 113 (2006) 946-952
28. Singh M., Williams B.A., Gersh B.J., et al. Geographical differences in the rates of angiographic restenosis and ischemia-driven target vessel revascularization after percutaneous coronary interventions: results from the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) Trial. J Am Coll Cardiol 47 (2006) 34-39
29. Spertus J., Safley D., Garg M., Jones P., and Peterson E.D. The influence of race on health status outcomes one year after an acute coronary syndrome. J Am Coll Cardiol 46 (2005) 1838-1844
30. Jha A.K., Fisher E.S., Li Z., Orav E.J., and Epstein A.M. Racial trends in the use of major procedures among the elderly. N Engl J Med 353 (2005) 683-691
31. Vaccarino V., Rathore S.S., Wenger N.K., et al. Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002. N Engl J Med 353 (2005) 671-682
32. Skinner J., Chandra A., Staiger D., Lee J., and McClellan M. Mortality after acute myocardial infarction in hospitals that disproportionately treat black patients. Circulation 112 (2005) 2634-2641
33. Barnato A.E., Lucas F.L., Staiger D., Wennberg D.E., and Chandra A. Hospital-level racial disparities in acute myocardial infarction treatment and outcomes. Med Care 43 (2005) 308-319
34. Lucas F.L., Stukel T.A., Morris A.M., Siewers A.E., and Birkmeyer J.D. Race and surgical mortality in the United States. Ann Surg 243 (2006) 281-286
35. Rathore S.S., Frederick P.D., Every N.R., Barron H.V., and Krumholz H.M. Racial differences in reperfusion therapy use in patients hospitalized with myocardial infarction: a regional phenomenon. Am Heart J 149 (2005) 1074-1081
36. Hertz R.P., Unger A.N., Cornell J.A., and Saunders E. Racial disparities in hypertension prevalence, awareness, and management. Arch Intern Med 165 (2005) 2098-2104
37. Tonne C., Schwartz J., Mittleman M., et al. Long-term survival after acute myocardial infarction is lower in more deprived neighborhoods. Circulation 111 (2005) 3063-3070
38. Shishehbor M.H., Litaker D., Pothier C.E., and Lauer M.S. Association of socioeconomic status with functional capacity, heart rate recovery, and all-cause mortality. JAMA 295 (2006) 784-792
39. Alter D.A., Chong A., Austin P.C., et al. Socioeconomic status and mortality after acute myocardial infarction. Ann Intern Med 144 (2006) 82-93
40. Spertus J., Decker C., Woodman C., et al. Effect of difficulty affording health care on health status after coronary revascularization. Circulation 111 (2005) 2572-2578
41. Hemingway H., McCallum A., Shipley M., et al. Incidence and prognostic implications of stable angina pectoris among women and men. JAMA 295 (2006) 1404-1411
42. Daly C., Clemens F., Lopez Sendon J.L., et al. Gender differences in the management and clinical outcome of stable angina. Circulation 113 (2006) 490-498
43. Smith C., Cowan C., Heffler S., and Catlin A. National health spending in 2004: recent slowdown led by prescription drug spending. Health Aff (Millwood) 25 (2006) 186-196
44. Lucas F.L., DeLorenzo M.A., Siewers A.E., and Wennberg D.E. Temporal trends in the utilization of diagnostic testing and treatments for cardiovascular disease in the United States, 1993-2001. Circulation 113 (2006) 374-379
45. Alter D.A., Stukel T.A., and Newman A. Proliferation of cardiac technology in Canada: a challenge to the sustainability of Medicare. Circulation 113 (2006) 380-387
46. Sanders G.D., Hlatky M.A., and Owens D.K. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 353 (2005) 1471-1480
47. Goldberger Z., Elbel B., McPherson C.A., Paltiel A.D., and Lampert R. Cost advantage of dual-chamber versus single-chamber cardioverter-defibrillator implantation. J Am Coll Cardiol 46 (2005) 850-857
48. Cram P., Vijan S., Katz D., and Fendrick A.M. Cost-effectiveness of in-home automated external defibrillators for individuals at increased risk of sudden cardiac death. J Gen Intern Med 20 (2005) 251-258
49. Feldman A.M., deLissovoy G., Bristow M.R., et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol 46 (2005) 2311-2321
50. Kaiser C., Brunner-La Rocca H.P., Buser P.T., et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 366 (2005) 921-929
51. Bagust A., Grayson A.D., Palmer N.D., Perry R.A., and Walley T. Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study. Heart 92 (2006) 68-74
52. Alexander K.P., Roe M.T., Chen A.Y., et al. Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 46 (2005) 1479-1487
53. Ko D.T., Tu J.V., Masoudi F.A., et al. Quality of care and outcomes of older patients with heart failure hospitalized in the United States and Canada. Arch Intern Med 165 (2005) 2486-2492
54. Newby L.K., LaPointe N.M., Chen A.Y., et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 113 (2006) 203-212
55. Watkins S., Thiemann D., Coresh J., et al. Fourteen-year (1987 to 2000) trends in the attack rates of, therapy for, and mortality from non-ST-elevation acute coronary syndromes in four United States communities. Am J Cardiol 96 (2005) 1349-1355
56. Lee D.S., Tu J.V., Juurlink D.N., et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 294 (2005) 1240-1247
57. Moscucci M., Rogers E.K., Montoye C., et al. Association of a continuous quality improvement initiative with practice and outcome variations of contemporary percutaneous coronary interventions. Circulation 113 (2006) 814-822
58. Zhang H., Alexander J.A., Luttrell J., et al. Data feedback and clinical process improvement in acute myocardial infarction. Am Heart J 149 (2005) 856-861
59. Goff Jr. D.C., Massing M.W., Bertoni A.G., et al. Enhancing quality of heart failure care in managed Medicare and Medicaid in North Carolina: results of the North Carolina Achieving Cardiac Excellence (NC ACE) Project. Am Heart J 150 (2005) 717-724
60. Butler J., Speroff T., Arbogast P.G., et al. Improved compliance with quality measures at hospital discharge with a computerized physician order entry system. Am Heart J 151 (2006) 643-653
61. Hillman K., Chen J., Cretikos M., et al. Introduction of the medical emergency team (MET) system: a cluster-randomised controlled trial. Lancet 365 (2005) 2091-2097
62. Beck C.A., Richard H., Tu J.V., and Pilote L. Administrative Data Feedback for Effective Cardiac Treatment: AFFECT, a cluster randomized trial. JAMA 294 (2005) 309-317
63. McNamara R.L., Herrin J., Bradley E.H., et al. Hospital improvement in time to reperfusion in patients with acute myocardial infarction, 1999 to 2002. J Am Coll Cardiol 47 (2006) 45-51
64. Nallamothu B.K., Bates E.R., Herrin J., et al. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 111 (2005) 761-767
65. Magid D.J., Wang Y., Herrin J., et al. Relationship between time of day, day of week, timeliness of reperfusion, and in-hospital mortality for patients with acute ST-segment elevation myocardial infarction. JAMA 294 (2005) 803-812
66. Curtis J.P., Portnay E.L., Wang Y., et al. The pre-hospital electrocardiogram and time to reperfusion in patients with acute myocardial infarction, 2000-2002: findings from the National Registry of Myocardial Infarction-4. J Am Coll Cardiol 47 (2006) 1544-1552
67. Bradley E.H., Roumanis S.A., Radford M.J., et al. Achieving door-to-balloon times that meet quality guidelines: how do successful hospitals do it?. J Am Coll Cardiol 46 (2005) 1236-1241
68. Audet A.M., Doty M.M., Shamasdin J., and Schoenbaum S.C. Measure, learn, and improve: physicians' involvement in quality improvement. Health Aff (Millwood) 24 (2005) 843-853
69. Hibbard J.H., Stockard J., and Tusler M. Hospital performance reports: impact on quality, market share, and reputation. Health Aff (Millwood) 24 (2005) 1150-1160
70. Moscucci M., Eagle K.A., Share D., et al. Public reporting and case selection for percutaneous coronary interventions: an analysis from two large multicenter percutaneous coronary intervention databases. J Am Coll Cardiol 45 (2005) 1759-1765
71. Rector T.S., Anand I.S., and Cohn J.N. Relationships between clinical assessments and patients' perceptions of the effects of heart failure on their quality of life. J Card Fail 12 (2006) 87-92
72. Luther S.A., McCullough P.A., Havranek E.P., et al. The relationship between B-type natriuretic peptide and health status in patients with heart failure. J Card Fail 11 (2005) 414-421
73. Heidenreich P.A., Spertus J.A., Jones P.G., et al. Health status identifies heart failure outpatients at risk for hospitalization or death. J Am Coll Cardiol 47 (2006) 752-756
74. McCrindle B.W., Williams R.V., Mitchell P.D., et al. Relationship of patient and medical characteristics to health status in children and adolescents after the Fontan procedure. Circulation 113 (2006) 1123-1129
75. Sleeper L.A., Ramanathan K., Picard M.H., et al. Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol 46 (2005) 266-273
76. Howard B.V., VanHorn L., Hsia J., et al. Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 295 (2006) 655-666
77. Howard B.V., Manson J.E., Stefanick M.L., et al. Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. JAMA 295 (2006) 39-49
78. Appel L.J., Sacks F.M., Carey V.J., et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA 294 (2005) 2455-2464
79. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., and Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295 (2006) 761-775
80. VanGaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., and Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
81. Ingelsson E., Sundstrom J., Arnlov J., Zethelius B., and Lind L. Insulin resistance and risk of congestive heart failure. JAMA 294 (2005) 334-341
82. Yusuf S., Hawken S., Ounpuu S., et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 366 (2005) 1640-1649
83. Lee I.M., Cook N.R., Gaziano J.M., et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 294 (2005) 56-65
84. Raitt M.H., Connor W.E., Morris C., et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA 293 (2005) 2884-2891
85. Carnethon M.R., Gulati M., and Greenland P. Prevalence and cardiovascular disease correlates of low cardiorespiratory fitness in adolescents and adults. JAMA 294 (2005) 2981-2988
86. Blumenthal J.A., Sherwood A., Babyak M.A., et al. Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial. JAMA 293 (2005) 1626-1634
87. Fleg J.L., Morrell C.H., Bos A.G., et al. Accelerated longitudinal decline of aerobic capacity in healthy older adults. Circulation 112 (2005) 674-682
88. Redfield M.M., Jacobsen S.J., Borlaug B.A., Rodeheffer R.J., and Kass D.A. Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation 112 (2005) 2254-2262
89. Ezzati M., Henley S.J., Thun M.J., and Lopez A.D. Role of smoking in global and regional cardiovascular mortality. Circulation 112 (2005) 489-497
90. Gregg E.W., Cheng Y.J., Cadwell B.L., et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 293 (2005) 1868-1874
91. Carroll M.D., Lacher D.A., Sorlie P.D., et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 294 (2005) 1773-1781
92. Arnett D.K., Jacobs Jr. D.R., Luepker R.V., et al. Twenty-year trends in serum cholesterol, hypercholesterolemia, and cholesterol medication use: the Minnesota Heart Survey, 1980-1982 to 2000-2002. Circulation 112 (2005) 3884-3891
93. Gu D., Reynolds K., Wu X., et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 365 (2005) 1398-1405
94. Halkin A., Singh M., Nikolsky E., et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol 45 (2005) 1397-1405
95. Wu C., Hannan E.L., Walford G., et al. A risk score to predict in-hospital mortality for percutaneous coronary interventions. J Am Coll Cardiol 47 (2006) 654-660
96. Clayton T.C., Lubsen J., Pocock S.J., et al. Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients. BMJ 331 (2005) 869-872
97. Daly C.A., DeStavola B., Sendon J.L., et al. Predicting prognosis in stable angina-results from the Euro heart survey of stable angina: prospective observational study. BMJ 332 (2006) 262-267
98. Lloyd-Jones D.M., Leip E.P., Larson M.G., et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 113 (2006) 791-798